Immunotherapy for early-stage small cell lung cancer that can be removed with surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving immunotherapy before and after surgery can help people with limited-stage small cell lung cancer. It is for patients whose cancer has not spread widely and can be completely removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have small cell lung cancer that has not spread beyond one side of the chest and can be fully removed with surgery
- You have not had any previous cancer treatment like chemotherapy, radiation, or surgery for this cancer
- You are willing and able to follow the study schedule and give written permission to take part
- You have a good performance status (able to do daily activities without help or with minimal help)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (adebrelimab), a targeted therapy (apatinib), and chemotherapy given before surgery for people with limited-stage small cell lung cancer. The goal is to see if this treatment shrinks the tumor enough to make surgery more effective and to study markers that might predict response.
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy, and targeted radiation (SBRT) before surgery for people with limited-stage small cell lung cancer. The goal is to see if this approach can shrink tumors and improve outcomes before the main treatment.
This trial tests whether adding two immunotherapy drugs (toripalimab and JS004) to standard chemotherapy before surgery can help shrink limited-stage small cell lung cancer. The goal is to find better ways to treat this cancer before surgery.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
This study is testing a new combination treatment for early-stage small-cell lung cancer. It compares giving immunotherapy drugs (PD-1/PD-L1 inhibitors) along with chemotherapy before surgery versus chemotherapy alone, to see if the combination helps shrink tumors more effectively and improves outcomes.
This trial tests a combination of an immunotherapy drug (tislelizumab) with standard chemotherapy (and sometimes radiation) for people with small cell lung cancer that has spread to only a few spots in the body. The goal is to see if adding immunotherapy helps control the cancer better than chemotherapy alone.
Hear when a new Perioperative Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.